INTRODUCTION: Isatin-5-sulfonamide ([(18)F]ICMT-11) is a sub-nanomolar inhibitor of caspase-3 previously evaluated as an apoptosis imaging agent. Herein, an alternative radiosynthesis of [(18)F]ICMT-11 with increased purity and specific activity is presented. Finally, a GMP-applicable automated radiosynthesis of [(18)F]ICMT-11 is described. METHODS: The preparation of [(18)F]ICMT-11 was evaluated under a variety of reaction conditions, including reaction solvent, by employing alternative phase transfer catalysts and under different deprotection conditions. Following initial investigations, the process was transferred onto a fully automated GE FASTlab synthesis platform for further development and optimisation. RESULTS: The synthesis of [(18)F]ICMT-11 was successfully validated under GMP conditions, resulting in a yield of 4.6 ± 0.4 GBq with a radiochemical purity of >98% at EOS and a specific activity of 685 ± 237 GBq/μmol within 90 min. Quality control was carried out in accordance with the European Pharmacopoeia and demonstrated that [(18)F]ICMT-11 can be consistently manufactured on the FASTlab to meet specifications. CONCLUSIONS: A simplified methodology for the synthesis of the apoptosis imaging agent, [(18)F]ICMT-11, has been achieved by the S(N)2 displacement of a tosylate leaving group with [(18)F]fluoride ion. This results in an increased purity and specific activity over the original copper catalysed "Click" synthetic stratagem reaction involving 2-[(18)F]fluoroethylazide with an alkyne precursor and is now suitable for routine clinical application.
INTRODUCTION:Isatin-5-sulfonamide ([(18)F]ICMT-11) is a sub-nanomolar inhibitor of caspase-3 previously evaluated as an apoptosis imaging agent. Herein, an alternative radiosynthesis of [(18)F]ICMT-11 with increased purity and specific activity is presented. Finally, a GMP-applicable automated radiosynthesis of [(18)F]ICMT-11 is described. METHODS: The preparation of [(18)F]ICMT-11 was evaluated under a variety of reaction conditions, including reaction solvent, by employing alternative phase transfer catalysts and under different deprotection conditions. Following initial investigations, the process was transferred onto a fully automated GE FASTlab synthesis platform for further development and optimisation. RESULTS: The synthesis of [(18)F]ICMT-11 was successfully validated under GMP conditions, resulting in a yield of 4.6 ± 0.4 GBq with a radiochemical purity of >98% at EOS and a specific activity of 685 ± 237 GBq/μmol within 90 min. Quality control was carried out in accordance with the European Pharmacopoeia and demonstrated that [(18)F]ICMT-11 can be consistently manufactured on the FASTlab to meet specifications. CONCLUSIONS: A simplified methodology for the synthesis of the apoptosis imaging agent, [(18)F]ICMT-11, has been achieved by the S(N)2 displacement of a tosylate leaving group with [(18)F]fluoride ion. This results in an increased purity and specific activity over the original copper catalysed "Click" synthetic stratagem reaction involving 2-[(18)F]fluoroethylazide with an alkyne precursor and is now suitable for routine clinical application.
Authors: Federica Pisaneschi; Lindsay E Kelderhouse; Amanda Hardy; Brian J Engel; Uday Mukhopadhyay; Carlos Gonzalez-Lepera; Joshua P Gray; Argentina Ornelas; Terry T Takahashi; Richard W Roberts; Stephen V Fiacco; David Piwnica-Worms; Steven W Millward Journal: Bioconjug Chem Date: 2017-02-02 Impact factor: 4.774
Authors: Anna A Rybczynska; Hendrikus H Boersma; Steven de Jong; Jourik A Gietema; Walter Noordzij; Rudi A J O Dierckx; Philip H Elsinga; Aren van Waarde Journal: Med Res Rev Date: 2018-03-12 Impact factor: 12.944
Authors: Vessela Vassileva; Stephen M Stribbling; Chris Barnes; Laurence Carroll; Marta Braga; Joel Abrahams; Kathrin Heinzmann; Caroline Haegeman; Marion MacFarlane; Kathryn L Simpson; Caroline Dive; Jamie Honeychurch; Timothy M Illidge; Eric O Aboagye Journal: EJNMMI Res Date: 2019-02-19 Impact factor: 3.138
Authors: Matthias Glaser; Vineeth Rajkumar; Seckou Diocou; Thibault Gendron; Ran Yan; Pak Kwan Brian Sin; Kerstin Sander; Laurence Carroll; R Barbara Pedley; Eric O Aboagye; Timothy H Witney; Erik Årstad Journal: Sci Rep Date: 2019-12-17 Impact factor: 4.379
Authors: S R Dubash; S Merchant; K Heinzmann; F Mauri; I Lavdas; M Inglese; K Kozlowski; N Rama; N Masrour; J F Steel; A Thornton; A K Lim; C Lewanski; S Cleator; R C Coombes; Laura Kenny; Eric O Aboagye Journal: Eur J Nucl Med Mol Imaging Date: 2018-09-27 Impact factor: 9.236